Why the study?
What is the incidence and mortality of anthracycline-induced cardiomyopathy in children?
What is the incidence and mortality of anthracycline-induced cardiomyopathy in children?
Anthracycline-induced cardiomyopathy in children has a notable incidence (5.3%) and a high mortality rate among affected patients.
Answers are grounded in this paper and cite their sources.
High mortality in affected children; leaves open optimal prevention strategies and requires prospective confirmation before practice change.
Although anthracycline antibiotics are among the most useful chemotherapy agents, the risk of producing cardiomyopathy and the absence of a reliable noninvasive technique to predict subclinical cardiomyopathy remain a major problem. We retrospectively reviewed our experience with anthracyclines over a 5-year period. Cardiomyopathy developed in 6 of 112 patients (5.3%) treated with anthracyclines and was fatal in 5 of the 6 patients. Our incidence and mortality rates are higher than those previously reported.
No takes yet. Share an insight, caveat, or question.
Dearth et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: